DR-327 Copy number features as a novel biomarker of homologous recombination (HR) status in HR deficient (HRD) tumors
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-327 Copy number features as a novel biomarker of homologous recombination (HR) status in HR deficient (HRD) tumors
Homologous recombination deficiency (HRD) is one of the driving factors of tumorigenesis as leads to damage in the repair process …
DR-328 Intratumoral microbiome characterisation to predict patient outcome in the context of immune-checkpoint inhibitors
Immune-checkpoint inhibitors are changing the treatment options for primary and metastatic tumor cancer patients. However, heterogeneity of response is observed …
DR-326 Cancer evolutionary dynamics
Cancers change over time. Understanding how cancers change is important for determining a patient’s prognosis and to improve the effectiveness …
DR-264 Genetic variation in the outcome of cancer
There were 18.1 million new cancer patients worldwide in 2020. Of these patients, some will recover after treatment while the …
DR-309 Unraveling the mystery of early-onset colorectal cancer
The incidence of early-onset colorectal cancer (eoCRC) in patients < 50 years of age is rapidly increasing. Despite indications that …
DR-318 The causes and consequences of structural variations in cancer
Structural variations (SVs) are large scale changes of DNA, which include deletions, duplications, inversion, translocations and other more complex forms. …
DR-315 Immune Surveillance in Metastases
The immune system constrains tumour growth. Cancer cells harbouring the capacity to evade the immune system are therefore selected. However, …
DR-313 Oncogenic pathways and their interaction with the immune system: prediction for response to combined therapies
We hypothesize that (in)activation of specific oncogenic pathways modulates the immune response to the tumor and initiates oncogenic pathway-specific immune …
DR-281 Identification of Cancer-Driving Mutations in Non-coding Regions
98% of our genome is non-coding and recent studies – including the landmark PCAWG analysis of 2,600 whole genomes – …
DR-307 The prevalence of homologous recombination deficiency (HRD) in sarcoma and its role as biomarker for PARP-inhibitor therapy
Soft tissue sarcoma treatment options are limited and prognosis is generally poor. It was recently shown that both osteosarcoma and …
DR-311 Whole Genome Sequencing for exploratory investigation of actionable mutations in AYA patients
Cancer in Adolescents and Young Adults (AYA, 18-39 years) differs potentially from other age groups in that AYA patients can …
DR-303 EP300/CREBBP mutations and MYB/MYC alteratations in cancer and their co-occurrence
Mutations in EP300/CREBBP and alterations in MYB and MYC are not uncommon in cancer. However, we do not know how often …
We willen het maximum aan informatie uit de tumor van de patiënt halen. Deze DNA-test is daarvoor het best beschikbare instrument. Er is maar één keer weefsel, een biopt, met voldoende tumorcellen nodig. Omdat het hele genoom wordt onderzocht, ook de gebieden in het DNA waarvan we nu nog niet weten of de gevonden afwijkingen belangrijk zijn, is deze DNA-test tumortype onafhankelijk en toekomstbestendig. Deze eigenschappen zijn de twee belangrijkste eigenschappen van WGS.